MedTrace Logo

Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent

NCT02870140 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1435

Last updated 2020-12-17

No results posted yet for this study

Summary

The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease. The patients will be followed through 3 years for major clinical events.

Conditions

  • Coronary Stenosis

Interventions

DEVICE

SUPRAFLEX

Percutaneous Coronary Intervention

DEVICE

XIENCE

Percutaneous Coronary Intervention

Sponsors & Collaborators

  • Sahajanand Medical Technologies Limited

    collaborator INDUSTRY

  • ECRI bv

    lead INDUSTRY

Principal Investigators

  • P. W. Serruys, Prof. MD. · International Center for Circulatory Health, NHLI, Imperial College, London, United Kingdom

  • U. Kaul, Prof. MD. · Fortis Escorts Heart Institute & Research Centre, New Delhi, India

  • R. de Winter, Prof. MD. · Academisch Medisch Centrum, Amsterdam, The Netherlands

  • A. Zaman, MD. · Cardiac Catheter Laboratories, Royal Freeman, Newcastle, United Kingdom

  • Ernest Spitzer, MD. · ECRI-Trials B.V. ([email protected])

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-21
Primary Completion
2018-09-20
Completion
2020-08-26

Countries

  • Bulgaria
  • Hungary
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02870140 on ClinicalTrials.gov